Clinical

Positive One-Year Results of PALS Program Published in Prestigious Rheumatology Journal

Retrieved on: 
Thursday, October 26, 2023
Linda, Knowledge, SLE, Trial of the century, American College, Stanford University, PALS, Bentham Science Publishers, Hope, Lupus Research Alliance, Ron Link (patient advocate), AUC, Research, Clinical trial, Lupus, University of North Carolina School of Law, Chapel Hill, Clinical, Disease, University, American College of Rheumatology, Therapy, Patient, Pharmaceutical industry, Medical device, Rheumatology, MD, HMS LCT 147

The PALS (Patient Advocates for Lupus Studies) Program was created to increase knowledge, positive attitudes toward, and intentions among people with lupus to join a clinical trial with the aim of increasing participation.

Key Points: 
  • The PALS (Patient Advocates for Lupus Studies) Program was created to increase knowledge, positive attitudes toward, and intentions among people with lupus to join a clinical trial with the aim of increasing participation.
  • These newly published results showed that one year after completing the PALS program, participants' knowledge about lupus clinical trials (LCTs) had significantly increased, and nearly half took some further action with regards to joining a trial.
  • *
    The study authors agree, concluding the results "suggest that the peer-support program is a promising means to educate patients with lupus about LCTs.
  • PALS, a peer-to-peer clinical trial education program, was co-designed with lupus patients and piloted at five academic medical centers belonging to the Lupus Therapeutics Lupus Clinical Investigators Network (LuCIN).

SystImmune, Inc. to Present New Oncology Pipeline Data at ESMO Congress 2023

Retrieved on: 
Saturday, October 21, 2023
ESMO, HER2, Congress, European Society for Medical Oncology, Candidate, American Society of Clinical Oncology, Society, Clinical, ADC, HER3, Spacecraft, Oncology, CMO, Patient, ASCO, EGFR, Vaccine, Nursing

The event is scheduled to take place from October 20th to 24th in Madrid, Spain, where new clinical findings will be unveiled from trials involving BL-B01D1 and BL-M07D1.

Key Points: 
  • The event is scheduled to take place from October 20th to 24th in Madrid, Spain, where new clinical findings will be unveiled from trials involving BL-B01D1 and BL-M07D1.
  • The expanded results from these clinical trials of BL-B01D1 will include data from patients with several solid tumor types in advanced stages and having multiple cycles of prior therapies.
  • The data presented at ESMO builds on previously reported clinical data at the American Society of Clinical Oncology (ASCO), and recent recognition for BL-B01D1 conferred by industry experts at the 14th Annual World ADC meeting in San Diego who recognized SystImmune's BL-B01D1 as a "Runner-Up" in the award category of "Most Promising Clinical Candidate".
  • Presentations at the ESMO congress include:

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

Retrieved on: 
Tuesday, October 17, 2023
Efficacy, Staphylococcus, Methicillin-resistant Staphylococcus aureus, Ambrose, Abstract, Treatment, Clinical, Circulatory system, MRSA, Biomedical Advanced Research and Development Authority, BARDA, Enterococcus faecalis, Infection, ASPR, MSSA, IDSA, Isolates, Laboratory, Liolios Xirolivaditis, Staphylococcus aureus, PK/PD models, SAB, ABSSSI, CABP, Bronchopneumonia, Administration for Strategic Preparedness and Response, Streptococcus pneumoniae, Prescription Drug User Fee Act, Duke University School of Medicine, Infectious Diseases Society of America, Randomness, Development, Administration, Safety, Patient, PDUFA, HHS, Pharmaceutical industry, Vaccine, Ceftobiprole, Litherland, Enterococcus, Allschwil, Streptococcus, Bloodstream infections

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at IDWeek provide further evidence for the potent antimicrobial activity of ceftobiprole against MRSA and other clinically relevant pathogens.

Key Points: 
  • Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at IDWeek provide further evidence for the potent antimicrobial activity of ceftobiprole against MRSA and other clinically relevant pathogens.
  • It also provides results of pharmacokinetic-pharmacodynamic modeling supporting the dosing regimens to treat severe bacterial infections from the successful clinical phase 3 studies.
  • Abstract #1946 – In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020) – L. Duncan, M. Castanheira, J. I.
  • Smart, M. E. Jones, P. G. Ambrose, K. Litherland
    Abstract #2561 – Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies – A. P. Cammarata, K. Litherland, M. C. Safir, S. M. Bhavnani, M. Saulay, J. I.

Clinical ink Introduces Breakthrough Solution to Drastically Reduce Study Build Timelines

Retrieved on: 
Thursday, October 12, 2023
Data management, Clinical, American Opportunity Tax Credit, EVP, Trial of the century, Medical imaging

Winston Salem, NC, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, is setting a new industry benchmark in advancing study build timelines.

Key Points: 
  • Winston Salem, NC, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, is setting a new industry benchmark in advancing study build timelines.
  • Harnessing the power of the latest eCOA technology, Clinical ink can now reduce study build timelines to as little as 10 days.
  • “Setting a 10-day benchmark in study build timelines is proof of the strength of the latest Clinical ink eCOA technology,” comments Megan Petrylak , EVP, Clinical Operations.
  • “Clinical ink is redefining speed and raising the bar for efficiency and accuracy, ensuring that clinical study development is agile and meticulous."

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

Retrieved on: 
Friday, October 6, 2023
Clinical Science (journal), Ludwig Maximilian University of Munich, Cancer, Dana–Farber Cancer Institute, Department of Medicine – University of Pamplona, Faculty, Research, Clinical, Therapy, Case Western Reserve University, Hospital, Nature, Melanoma, Journal, Nivolumab, Carcinoma, Brigham and Women's Hospital, Harvard Medical School, Clinical trial, Associate, American Journal of Clinical Oncology, Principal investigator, Neoplasm, Patient, Vaccine, Pharmaceutical industry, New York University, Medicine

LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.

Key Points: 
  • LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.
  • Dr. Ott is the Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute.
  • He joins current scientific advisory board members Dan H. Barouch, M.D., Ph.D., Luke D. Handke, Ph.D., Sachet A. Shukla, Ph.D. and John W. Shiver, Ph.D.
    “We are honored that Dr. Ott has agreed to our scientific advisory board and believe that he will offer invaluable guidance as we further develop our technologies and advance our pipeline,” said Dr. Corinne Le Goff, president and chief executive officer of IMUNON.
  • Dr. Ott has been Principal Investigator of a first-in-human clinical trial testing a personalized vaccine (NeoVax) in patients with melanoma.

Neurona Therapeutics Announces Publication in Cell Stem Cell Reporting the Development of Investigational Novel Regenerative Cell Therapy Strategy for Drug-resistant Focal Epilepsy

Retrieved on: 
Thursday, October 5, 2023
Interneuron, Neuropathology, Temporal lobe epilepsy, RNA, Clinical, Cell, GABAergic, B cell, DSM-IV codes, Survival, MGE, Generalized tonic–clonic seizure, Epilepsy, Transplant, Translation, GMP, Cell Stem Cell, Therapy, GABA, Seizure, Clinical trial, History, SAN, Tissue, Behavior informatics, Patient, Pharmaceutical industry, Vaccine, Sarcocystis neurona

SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the publication of the development and characterization of a highly purified population of human stem cell-derived, pallial-specific MGE inhibitory interneurons for the potential treatment of focal epilepsy. In a preclinical study, administration of a single dose of the cells in a chronic model of drug-resistant MTLE resulted in durable and consistent suppression of focal seizures, as well as improvements in neuropathology and an increase in survival of the model. The study also demonstrated a potentially broad, safe and effective dosing range in the preclinical model. The data support the development of Neurona Therapeutics’ regenerative cell therapy candidate, NRTX-1001, which is being evaluated in an ongoing Phase I/II clinical trial of a one-time dose in subjects with drug-resistant MTLE (NCT05135091). The preclinical data were published today in Cell Stem Cell as a Clinical and Translational Report titled “Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy” by first authors Bershteyn, Bröer, Parekh, Maury, and colleagues and is available online.

Key Points: 
  • The data support the development of Neurona Therapeutics’ regenerative cell therapy candidate, NRTX-1001, which is being evaluated in an ongoing Phase I/II clinical trial of a one-time dose in subjects with drug-resistant MTLE ( NCT05135091 ).
  • The preclinical data were published today in Cell Stem Cell as a Clinical and Translational Report titled “Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy” by first authors Bershteyn, Bröer, Parekh, Maury, and colleagues and is available online .
  • “We are thrilled to announce this landmark publication, which builds the foundation for NRTX-1001 and exemplifies the phenomenal science being conducted by Neurona employees.
  • The data support the development of Neurona’s cell therapy candidate NRTX-1001, which is being evaluated in an ongoing clinical trial ( NCT05135091 ) in adults with drug-resistant MTLE.

Augmedix Forging Strategic Partnerships for an Open Network of Digital Health Solutions

Retrieved on: 
Thursday, October 5, 2023
Triage, Partnership, Health, Clinical, API, Heart, Natural language processing, Clinical decision support system, Patient safety, Documentation, SDOH, CDSS, Emergency medicine, Malpractice, Depression, SAN, EHR, ROI, Patient, Medical device

The goal of these partnerships is to enhance the value delivered to health systems by forging an open network of digital health solutions that will integrate into Augmedix’s technology through application programming interfaces (APIs), structured data feeds, and Augmedix’s bi-directional communication channel into the point of care.

Key Points: 
  • The goal of these partnerships is to enhance the value delivered to health systems by forging an open network of digital health solutions that will integrate into Augmedix’s technology through application programming interfaces (APIs), structured data feeds, and Augmedix’s bi-directional communication channel into the point of care.
  • “Partnering with these healthcare innovators represents our commitment to drive transformation through open collaborations and integrations,” said Ian Shakil, Founder, Director, and Chief Strategy Officer of Augmedix.
  • Augmedix and Ellipsis Health expect to be able to automate medical documentation, mental health screenings, social determinants of health (SDOH) screenings, and topic analysis to help to identify issues earlier and triage patients to the appropriate care.
  • They will also enable Augmedix to further leverage the wealth of structured data created by its platform and will serve to enhance health system ROI and patient outcomes.

Twenty-Three Hospitals in North Dakota Form New Network to Strengthen Rural Healthcare

Retrieved on: 
Thursday, October 12, 2023
Managed Care, Hospitals, General Health, Health, Ophthalmology, CIN, Hospital, Obstetrics, Clinical, Health information exchange, Patient, Mental health, Rough Riders, Information technology, Pharmacy, CIC, Sams, Physician, BIC, Health insurance, Management, Health care, Nursing

Leaders from Rough Rider HVN and its member hospitals have been collaborating to develop the network for more than a year.

Key Points: 
  • Leaders from Rough Rider HVN and its member hospitals have been collaborating to develop the network for more than a year.
  • The Rough Rider HVN’s aim is to enable rural hospitals to band together to meet the increasing challenges of delivering healthcare in rural communities.
  • The network received state funding of $3.5 million to help facilitate Rough Rider’s capabilities to support North Dakota patients and hospitals in the transition to value-based care.
  • Through the Rough Rider CIN, member hospitals will be able to coordinate seamless care for patients across the network.

College of American Pathologists Honors 29 Members/Residents at CAP23 Annual Meeting

Retrieved on: 
Saturday, October 7, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Virginia House of Delegates, College, Consultant (medicine), Clinical, Accreditation, Illinois Department of Veterans' Affairs, Human services, CAP, Engineer Research and Development Center, Council, Marie Cassidy, Education, Member, College of American Pathologists, Pathology, Illinois Department of Human Services, HOD, House, National Council for Accreditation of Teacher Education, Patient, Property management, Nursing, MD, Southern Illinois University

The College of American Pathologists (CAP), the world’s largest organization of board-certified pathologists and the leading provider of laboratory accreditation and proficiency testing programs, honored several of its members for their contributions to pathology and laboratory medicine during its annual meeting, in Chicago, Illinois October 7-10, 2023.

Key Points: 
  • The College of American Pathologists (CAP), the world’s largest organization of board-certified pathologists and the leading provider of laboratory accreditation and proficiency testing programs, honored several of its members for their contributions to pathology and laboratory medicine during its annual meeting, in Chicago, Illinois October 7-10, 2023.
  • In recognition of her long and distinguished career in pathology, the CAP named Bharati Suketu Jhaveri, MD, FCAP, Pathologist of the Year.
  • Dr. Jhaveri has devoted much of her professional life to the CAP.
  • “I am grateful to be recognized for this prestigious award from the College of American Pathologists and consider this award encouragement to continue,” shares Dr. Jhaveri.

Atrium Health: AI Solution Improved Documentation Experience for Almost 85% of Physicians

Retrieved on: 
Tuesday, October 10, 2023
Investment, Hospital, Microsoft, Physician, Burn, Job satisfaction, Clinical, Atrium Health, Licensure, Health, LAS, Cancer, Atrium, Patient, Electronic health record, Documentation, Nursing, Interface (computing), Fatigue, EHR, Conference, Electronic health records in the United States, Nuance

LAS VEGAS, Oct. 10, 2023 /PRNewswire/ -- Clinical leaders at Atrium Health have long embraced a concept they call "Best Place to Care." As part of that initiative, Atrium Health surveys their providers to understand how to make the job more enjoyable and avoid burnout. One of the top concerns among providers is how much time they spend doing administrative tasks.

Key Points: 
  • Atrium Health is the first health system in the nation to deploy an artificial intelligence tool designed to automate the creation of clinical documentation during patient visits.
  • Leaders from Atrium Health and Nuance discussed the solution today at the 2023 HLTH Conference , in Las Vegas.
  • Based in Charlotte, North Carolina, Atrium Health has deployed DAX Copilot to its primary care physicians with plans for a broad roll-out across its footprint.
  • Atrium Health physicians are already reporting saving up to 40 minutes per day with this advanced documentation assistant.